Securing Data in Technology Transactions: The 10 Most Important Provisions to Include in Your Contracts
October 6, 2010
Please join us for a Foley Executive Briefing Series program that will explore strategies for protecting your electronic information during technology transactions, and provide practical tips and take-away materials that you can begin implementing into your technology contracts immediately.
Topics to be addressed include:
- An overview of the data security landscape — new developments, hot topics, and common issues
- How data security should be addressed in contracts
- Tips for drafting and negotiating the critical data security provisions that must be included in contracts
- Real-world and practical examples of the necessary provisions
These and other topics will be addressed in an informal, interactive panel session led by Foley Intellectual Property Senior Counsel Matthew A. Karlyn and Peter F. McLaughlin.
“Securing Data in Technology Transactions: The 10 Most Important Provisions to Include in Your Contracts” is part of the Foley Executive Briefing Series. Learn more about programs in the series at Foley.com/FEBS.
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.